Vistagen Therapeutics, Inc.
No enriched coverage for $VTGN in the last 7 days.
No SEC Form 4 filings for $VTGN in the last 30 days.
See all $VTGN insider activity →Vistagen Therapeutics, Inc. (VTGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update Exploratory analyses of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement in recently reported clinical studies FDA eng
Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.
SRX Global Inc. (SRXH) said it acquired a stake in Vistagen Therapeutics (VTGN), a late clinical-stage neuroscience biopharma developing intranasal “pherines” for CNS disorders. SRXH said it views VTGN as undervalued and plans constructive engagement with management and the board. VTGN closed at $0.24 and was $0.37 in pre-market.
Recent VTGN coverage spans financial news, earnings and corporate actions.
Near-term trading focus is likely on fasedienol registrational pathway discussions with the FDA and cash runway guidance, alongside exploratory clinical readouts.
The news may improve sentiment and potentially catalyze governance or strategic discussions.
The announcement is a direct shareholder-value narrative catalyst for VTGN, but liquidity and microcap volatility may dominate price action.
The filing updates/extends director and officer indemnification and expense-advancement terms, which is typically low immediate earnings impact but can affect governance and litigation risk perception.
A missed goal can be a negative catalyst, but the scrape lacks the specific goal and context.
alphai scores every news story that mentions VTGN with an AI model for sentiment and relevance, and aggregates insider trades from Vistagen Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Vistagen Therapeutics, Inc. (VTGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update Exploratory analyses of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement in recently reported clinical studies FDA eng
6 min readBiotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.
7 min readSRX Global Inc. (SRXH) said it acquired a stake in Vistagen Therapeutics (VTGN), a late clinical-stage neuroscience biopharma developing intranasal “pherines” for CNS disorders. SRXH said it views VTGN as undervalued and plans constructive engagement with management and the board. VTGN closed at $0.24 and was $0.37 in pre-market.
3 min readVistagen Therapeutics, Inc. (VTGN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EXHIBIT 99.1 Vistagen Appoints Douglas J. Williamson to its Board of Directors Dr. Williamson brings nearly three decades of leadership experience in neuroscience drug development, clinical research, and regulatory strategy SOUTH SAN FRANCISCO, Calif.--(GLOBE NEWSWIRE)—July 31, 2
2 min readBiotech weekly roundup: Vertex Pharmaceuticals received FDA approval to expand Casgevy use for sickle cell disease and TDT, adding about 5,500 eligible U.S. children, and Apotex Health gained Health Canada approval for a generic semaglutide (SEVMIA). Unicycive Therapeutics fell after a second CRL for OLC in hyperphosphatemia; Ipsen and Vistagen also had deal/goal updates.
4 min readVistagen Therapeutics (VTGN) said its PALISADE-4 Phase 3 trial of fasedienol missed primary/secondary endpoints in 238 patients with social anxiety. Primary SUDS change was -9.5 vs -11.4 for placebo (p=0.427). A post-hoc subgroup with very severe social anxiety (n=123) showed nominal benefit (p=0.036). Company plans FDA talks on a revised registrational strategy and said cash of $45.4M funds operations into 2027.
4 min readVistagen Therapeutics, Inc. (VTGN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. vtgn-20260616 FALSE 0001411685 0001411685 2024-09-23 2024-09-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported):
2 min readVistagen Therapeutics, Inc. (VTGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 vtgn-20260615xex991.htm EX-99.1 Document Exhibit 99.1 Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update Completed randomized portion of PALISADE-4 Phase 3 trial of fasedienol for the acute treatment of social anxiety disorder; topline res
6 min readVistaGen Therapeutics has appointed Angel S. Angelov, M.D., MBA, as its new Chief Medical Officer, effective May 18, 2026. This appointment aims to bolster the company's efforts in advancing its neuropsychiatric and women's health programs, including pherine candidates in late-stage development. Angelov brings over two decades of clinical development experience from various pharmaceutical companies.
2 min readVistagen Therapeutics, Inc. reported a material event in an 8-K filing, detailing the approval of retention awards in the form of stock option grants for all employees. Key executives, including the CEO, CLO, Chief Corporate Development Officer, COO, and CFO, each received options to purchase up to 75,000 shares of common stock. These options were granted on April 7, 2026, with an exercise price of $0.5358 per share, and will vest over two years in 25% increments every six months.
2 min read
